Literature DB >> 16835973

Noninvasive treatment of uterine fibroids: early Mayo Clinic experience with magnetic resonance imaging-guided focused ultrasound.

Gina K Hesley1, Joel P Felmlee, John B Gebhart, Kelly T Dunagan, Krzysztof R Gorny, Jessica B Kesler, Kathleen R Brandt, Janel N Glantz, Bobbie S Gostout.   

Abstract

Uterine fibroids often cause symptoms of pelvic pain, pressure, and bleeding. Traditional therapies have included medical (eg, hormonal therapy) and surgical (eg, myomectomy, hysterectomy) options. Recently, uterine artery embolization was added to the treatment armamentarium. We describe an exciting new non-invasive treatment option using focused ultrasound with magnetic resonance imaging and summarize the early experience at the Mayo Clinic in Rochester, Minn, during the initial research studies of this new technology.

Entities:  

Mesh:

Year:  2006        PMID: 16835973     DOI: 10.4065/81.7.936

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  28 in total

1.  Comparison between diffusion-weighted imaging, T2-weighted, and postcontrast T1-weighted imaging after MR-guided, high intensity, focused ultrasound treatment of uterine leiomyomata: preliminary results.

Authors:  Michael A Jacobs; David H Gultekin; Hyun S Kim
Journal:  Med Phys       Date:  2010-09       Impact factor: 4.071

2.  Combining split-and-merge and multi-seed region growing algorithms for uterine fibroid segmentation in MRgFUS treatments.

Authors:  Leonardo Rundo; Carmelo Militello; Salvatore Vitabile; Carlo Casarino; Giorgio Russo; Massimo Midiri; Maria Carla Gilardi
Journal:  Med Biol Eng Comput       Date:  2015-11-03       Impact factor: 2.602

Review 3.  Reproductive impact of MRI-guided focused ultrasound surgery for fibroids: a systematic review of the evidence.

Authors:  Natalie A Clark; Sunni L Mumford; James H Segars
Journal:  Curr Opin Obstet Gynecol       Date:  2014-06       Impact factor: 1.927

Review 4.  Uterine fibroid therapy using interventional radiology mini-invasive treatments: current perspective.

Authors:  Carlo Masciocchi; Francesco Arrigoni; Fabiana Ferrari; Aldo Victor Giordano; Sonia Iafrate; Ilaria Capretti; Ester Cannizzaro; Alfonso Reginelli; Anna Maria Ierardi; Chiara Floridi; Alessio Salvatore Angileri; Luca Brunese; Antonio Barile
Journal:  Med Oncol       Date:  2017-02-24       Impact factor: 3.064

Review 5.  Review of influential clinical factors in reducing the risk of unsuccessful MRI-guided HIFU treatment outcome of uterine fibroids.

Authors:  Nguyen Minh Duc; Bilgin Keserci
Journal:  Diagn Interv Radiol       Date:  2018-09       Impact factor: 2.630

Review 6.  Medical treatment of uterine leiomyoma.

Authors:  Mohamed Sabry; Ayman Al-Hendy
Journal:  Reprod Sci       Date:  2012-02-28       Impact factor: 3.060

7.  Magnetic resonance-guided focused ultrasound of uterine leiomyomas: review of a 12-month outcome of 130 clinical patients.

Authors:  Krzysztof R Gorny; David A Woodrum; Douglas L Brown; Tara L Henrichsen; Amy L Weaver; Kimberly K Amrami; Nicholas J Hangiandreou; Heidi A Edmonson; Esther V Bouwsma; Elizabeth A Stewart; Bobbie S Gostout; Dylan A Ehman; Gina K Hesley
Journal:  J Vasc Interv Radiol       Date:  2011-04-08       Impact factor: 3.464

Review 8.  Magnetic Resonance-Guided High-Intensity Focused Ultrasound (MRgHIFU) Treatment of Symptomatic Uterine Fibroids: An Evidence-Based Analysis.

Authors:  G Pron
Journal:  Ont Health Technol Assess Ser       Date:  2015-03-01

Review 9.  Clinical and Technical Aspects of MR-Guided High Intensity Focused Ultrasound for Treatment of Symptomatic Uterine Fibroids.

Authors:  Laura E Rueff; Steven S Raman
Journal:  Semin Intervent Radiol       Date:  2013-12       Impact factor: 1.513

10.  Cost-effectiveness of magnetic resonance guided focused ultrasound for the treatment of uterine fibroids.

Authors:  Amy K O'Sullivan; David Thompson; Paula Chu; David W Lee; Elizabeth A Stewart; Milton C Weinstein
Journal:  Int J Technol Assess Health Care       Date:  2009-01       Impact factor: 2.188

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.